[1] |
Joensuu H, Hohenberger P, Corless CL. Gastrointestinal stromal tumour[J]. Lancet, 2013, 382(9896):973-983.
doi: 10.1016/S0140-6736(13)60106-3
pmid: 23623056
|
[2] |
Corless CL. Gastrointestinal stromal tumors: what do we know now?[J]. Mod Pathol, 2014, 27(Suppl 1):S1-S16.
doi: 10.1038/modpathol.2013.173
URL
|
[3] |
徐佳, 赵文毅, 庄淳, 等. 胃肠道间质瘤术后伊马替尼辅助治疗停药后复发的危险因素分析[J]. 中国普通外科杂志, 2016, 31(2):104-107.
|
[4] |
Shen YY, Ma XL, Wang M, et al. Exon 11 homozygous mutations and intron 10/exon 11 junction deletions in the KIT gene are associated with poor prognosis of patients with gastrointestinal stromal tumors[J]. Cancer Med, 2020, 9(18):6485-6496.
doi: 10.1002/cam4.3212
URL
|
[5] |
Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors[J]. N Engl J Med, 2002, 347(7):472-480.
doi: 10.1056/NEJMoa020461
URL
|
[6] |
Nishida T, Blay JY, Hirota S, et al. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines[J]. Gastric Cancer, 2016, 19(1):3-14.
doi: 10.1007/s10120-015-0526-8
URL
|
[7] |
Debiec-Rychter M. Sunitinib--a new approach following failure of imatinib in patients with advanced gastrointestinal stromal tumor[J]. Nat Clin Pract Oncol, 2007, 4(6):342-343.
doi: 10.1038/ncponc0814
URL
|
[8] |
Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship[J]. Clin Cancer Res, 2003, 9(1):327-337.
pmid: 12538485
|
[9] |
Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2013, 381(9863):295-302.
doi: 10.1016/S0140-6736(12)61857-1
pmid: 23177515
|
[10] |
George S, Jones RL, Bauer S, et al. Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy[J]. Oncologist, 2021, 26(4):e639-e649.
doi: 10.1002/onco.13674
URL
|
[11] |
Falkenhorst J, Hamacher R, Bauer S. New therapeutic agents in gastrointestinal stromal tumours[J]. Curr Opin Oncol, 2019, 31(4):322-328.
doi: 10.1097/CCO.0000000000000549
pmid: 31033566
|
[12] |
Joensuu H, DeMatteo RP. The management of gastrointestinal stromal tumors: a model for targeted and multidisciplinary therapy of malignancy[J]. Annu Rev Med, 2012, 63:247-258.
doi: 10.1146/annurev-med-043010-091813
pmid: 22017446
|
[13] |
中国胃肠道间质瘤病理共识意见专家组. 中国胃肠道间质瘤诊断治疗专家共识(2017年版)病理解读[J]. 中华病理学杂志, 2018, 47(1):2-6.
|
[14] |
许海敏, 陈晓炎, 董磊, 等. 不同克隆号 ALK 抗体在炎性肌纤维母细胞肿瘤中的表达比较研究[J]. 诊断病理学杂志, 2020, 27(9):629-632,636.
|
[15] |
Sihto H, Sarlomo-Rikala M, Tynninen O, et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors[J]. J Clin Oncol, 2005, 23(1):49-57.
doi: 10.1200/JCO.2005.02.093
URL
|
[16] |
Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor[J]. Hum Pathol, 2008, 39(10):1411-1419.
doi: 10.1016/j.humpath.2008.06.025
pmid: 18774375
|
[17] |
Nannini M, Tarantino G, Indio V, et al. Molecular mode-lling evaluation of exon 18 His845_Asn848delinsPro PDGFRα mutation in a metastatic GIST patient respon-ding to imatinib[J]. Sci Rep, 2019, 9(1):2172.
doi: 10.1038/s41598-018-38028-x
URL
|
[18] |
Wang M, Xu J, Zhao W, et al. Prognostic value of mutational characteristics in gastrointestinal stromal tumors: a single-center experience in 275 cases[J]. Med Oncol, 2014, 31(1):819.
doi: 10.1007/s12032-013-0819-x
URL
|
[19] |
Wozniak A, Rutkowski P, Schöffski P, et al. Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST[J]. Clin Cancer Res, 2014, 20(23):6105-6116.
doi: 10.1158/1078-0432.CCR-14-1677
URL
|
[20] |
Martin-Broto J, Gutierrez A, Garcia-Del-Muro X, et al. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study[J]. Ann Oncol, 2010, 21(7):1552-1557.
doi: S0923-7534(19)39490-6
pmid: 20231303
|
[21] |
中国临床肿瘤学会胃肠间质瘤专家委员会. 中国胃肠间质瘤诊断治疗共识(2017年版)[J]. 肿瘤综合治疗电子杂志, 2018, 4(1):31-43.
|
[22] |
Artigiani Neto R, Logullo AF, Stávale JN, et al. Ki-67 expression score correlates to survival rate in gastrointestinal stromal tumors(GIST)[J]. Acta Cir Bras, 2012, 27(5):315-321.
doi: S0102-86502012000500007
pmid: 22666745
|
[23] |
朱从波, 廖国庆, 赵丁民. Ki-67对胃肠道间质瘤预后的评估价值[J]. 临床与病理杂志, 2018, 38(8):1632-1639.
|
[24] |
Heinrich MC, Rankin C, Blanke CD, et al. Correlation of long-term results of imatinib in advanced gastrointestinal stromal tumors with next-generation sequencing results: analysis of Phase 3 SWOG Intergroup Trial S0033[J]. JAMA Oncol, 2017, 3(7):944-952.
doi: 10.1001/jamaoncol.2016.6728
pmid: 28196207
|
[25] |
Vanden Bempt I, Vander Borght S, Sciot R, et al. Comprehensive targeted next-generation sequencing approach in the molecular diagnosis of gastrointestinal stromal tumor[J]. Genes Chromosomes Cancer, 2021, 60(4):239-249.
doi: 10.1002/gcc.22923
URL
|
[26] |
孟琳, 张声. KIT基因双突变在胃肠道间质瘤中的作用[J]. 临床与病理杂志, 2018, 38(4): 830-836.
|
[27] |
Bosbach B, Deshpande S, Rossi F, et al. Imatinib resistance and microcytic erythrocytosis in a KitV558Δ;T669I/+ gatekeeper-mutant mouse model of gastrointestinal stromal tumor[J]. Proc Natl Acad Sci U S A, 2012, 109(34):E2276-E2283.
|
[28] |
Kang DY, Park CK, Choi JS, et al. Multiple gastrointestinal stromal tumors: clinicopathologic and genetic analysis of 12 patients[J]. Am J Surg Pathol, 2007, 31(2):224-232.
doi: 10.1097/01.pas.0000213318.66800.94
URL
|
[29] |
Xu C, Liu YL, Yu HY, et al. Synchronous and metachronous multiple gastrointestinal stromal tumors[J]. Histol Histopathol, 2012, 27(2):225-234.
|